Research and Markets (http://www.researchandmarkets.com/research/xlm44r/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering.

The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • Acceleron Pharma, Inc.
  • Angion Biomedica Corp.
  • Apceth GmbH & Co. KG
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-inRen
  • Boryung Pharmaceutical Co., Ltd.
  • Complexa, Inc.
  • Eli Lilly and Company
  • Evotec AG
  • Intercept Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • La Jolla Pharmaceutical Company
  • Lupin Limited
  • Nippon Zoki Pharmaceutical Co., Ltd.
  • OPKO Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • Prismic Pharmaceuticals, Inc.
  • Prolong Pharmaceuticals
  • ProMetic Life Sciences Inc.
  • Reata Pharmaceuticals, Inc.
  • Red Glead Discovery AB
  • RegenMedTX, LLC
  • Resverlogix Corp.
  • Sphaera Pharma Pvt. Ltd.
  • Stelic Institute & Co.
  • Thrasos Therapeutics Inc.
  • Toray Industries, Inc.
  • VBS Pharmaceuticals
  • Vicore Pharma AB

For more information visit http://www.researchandmarkets.com/research/xlm44r/chronic_kidney